RESUMEN
N-Nitrosamines are potent carcinogens and considered non-threshold carcinogens in various regulatory domains. However, recent data indicate the existence of a threshold for genotoxicity, which can be adequately demonstrated. This aspect has a critical impact on selecting the methodology that is applied to derive occupational exposure limits (OELs). OELs are used to protect workers potentially exposed to various chemicals by supporting the selection of appropriate control measures and ultimately reducing the risk of occupational cancer. Occupational exposures to nitrosamines occur during manufacturing processes, mainly in the rubber and chemical industry. The present study derives OELs for inhaled N-nitrosamines, employing the benchmark dose (BMD) approach if data are adequate and read-across for nitrosamines without adequate data. Additionally, benchmark dose lower confidence limit (BMDL) is preferred and more suitable point-of-departure (PoD) to calculate human health guidance values, including OEL. The lowest OEL (0.2 µg/m3 ) was derived for nitrosodiethylamine (NDEA), and nitrosopiperidine (NPIP) (OEL = 0.2 µg/m3 ), followed by nitrosopyrrolidine (NPYR) (0.4 µg/m3 ), nitrosodimethylamine (NDMA), nitrosodimethylamine (NMEA), and nitrosodipropylamine (NDPA) (0.5 µg/m3 ), nitrosomorpholine (NMOR) (OEL = 1 µg/m3 ), and nitrosodibutylamine (NDBA) (OEL = 2.5 µg/m3 ). Limits based on "non-threshold" TD50 slope calculation were within a 10-fold range. These proposed OELs do not consider skin absorption of nitrosamines, which is also a possible route of entry into the body, nor oral or other environmental sources. Furthermore, we recommend setting a limit for total nitrosamines based on the occupational exposure scenario and potency of components.
Asunto(s)
Nitrosaminas , Exposición Profesional , Humanos , Carcinógenos/toxicidad , Dimetilnitrosamina , Benchmarking , Nitrosaminas/toxicidad , Dietilnitrosamina , Exposición Profesional/efectos adversosRESUMEN
Endogenous substances, such as fatty, amino, and nucleic acids, are often purposefully used in parenterally pharmaceuticals, but may be present as impurities. Currently, no consensus guidance exists on setting impurity limits for these substances. Specific procedures are needed, as the amount and types of toxicity data available for endogenous substances are typically far less than those for other chemical impurities. Additionally, the parenteral route of administration of these substances is inherently non-physiological, resulting in potentially different or increased severity of toxicity. Risk Assessment Process Maps (RAPMAPs) are proposed as a model to facilitate the development of health-based exposure limits (HBELs) for endogenous substances. This yielded a framework that was applied to derive HBELs for several fatty acids commonly used in parenteral pharmaceuticals. This approach was used to derive HBELs with further vetting based on anticipated perturbations in physiological serum levels, impacts of dose-rate, and consideration of intermittent dosing. Parenteral HBELs of 100-500 mg/day were generated for several fatty acids, and a proposed class-based limit of 50 mg/day to be used in the absence of chemical-specific data. This default limit is consistent with the low toxicity of this chemical class and ICH Q3C value for Class 3 solvents.
Asunto(s)
Contaminación de Medicamentos , Ácidos Grasos , Preparaciones Farmacéuticas , Medición de RiesgoRESUMEN
Cross-contamination in multi-product pharmaceutical manufacturing facilities can impact both product safety and quality. This issue has been recognized by regulators and industry for some time, leading to publication of a number of continually evolving guidelines. This manuscript provides a historical overview of the regulatory framework for managing cross-contamination in multi-product facilities to provide context for current approaches. Early guidelines focused on the types of pharmaceuticals for which dedicated facilities and control systems were needed, and stated the requirements for cleaning validation. More recent guidelines have promoted the idea of using Acceptable Daily Exposures (ADEs) to establish cleaning limits for actives and other potentially hazardous substances. The ADE approach is considered superior to previous methods for setting cleaning limits such as using a predetermined general limit (e.g., 10 ppm or a fraction of the median lethal dose (LD50) or therapeutic dose). The ADEs can be used to drive the cleaning process and as part of the overall assessment of whether dedicated production facilities are required. While great strides have been made in using the ADE approach, work remains to update good manufacturing practices (GMPs) to ensure that the approaches are clear, consistent with the state-of-the-science, and broadly applicable yet flexible enough for adaptation to unique products and situations.
Asunto(s)
Contaminación de Medicamentos/prevención & control , Industria Farmacéutica , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas/análisis , Animales , Difusión de Innovaciones , Contaminación de Medicamentos/legislación & jurisprudencia , Industria Farmacéutica/historia , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Industria Farmacéutica/tendencias , Predicción , Guías como Asunto , Política de Salud , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/historia , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Salud Laboral/tendencias , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Control de Calidad , Medición de Riesgo , Pruebas de ToxicidadRESUMEN
This manuscript centers on communication with key stakeholders of the concepts and program goals involved in the application of health-based pharmaceutical cleaning limits. Implementation of health-based cleaning limits, as distinct from other standards such as 1/1000th of the lowest clinical dose, is a concept recently introduced into regulatory domains. While there is a great deal of technical detail in the written framework underpinning the use of Acceptable Daily Exposures (ADEs) in cleaning (for example ISPE, 2010; Sargent et al., 2013), little is available to explain how to practically create a program which meets regulatory needs while also fulfilling good manufacturing practice (GMP) and other expectations. The lack of a harmonized approach for program implementation and communication across stakeholders can ultimately foster inappropriate application of these concepts. Thus, this period in time (2014-2017) could be considered transitional with respect to influencing best practice related to establishing health-based cleaning limits. Suggestions offered in this manuscript are intended to encourage full and accurate communication regarding both scientific and administrative elements of health-based ADE values used in pharmaceutical cleaning practice. This is a large and complex effort that requires: 1) clearly explaining key terms and definitions, 2) identification of stakeholders, 3) assessment of stakeholders' subject matter knowledge, 4) formulation of key messages fit to stakeholder needs, 5) identification of effective and timely means for communication, and 6) allocation of time, energy, and motivation for initiating and carrying through with communications.
Asunto(s)
Industria Farmacéutica , Comunicación Interdisciplinaria , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Animales , Conducta Cooperativa , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Guías como Asunto , Política de Salud , Humanos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Objetivos Organizacionales , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Desarrollo de Programa , Medición de Riesgo , Pruebas de ToxicidadRESUMEN
A European Union (EU) regulatory guideline came into effect for all new pharmaceutical products on June 1st, 2015, and for all existing pharmaceutical products on December 1st, 2015. This guideline centers around the use of the Acceptable Daily Exposure (ADE) [synonymous with the Permitted Daily Exposure (PDE)] and operational considerations associated with implementation are outlined here. The EU guidance states that all active pharmaceutical ingredients (API) require an ADE; however, other substances such as starting materials, process intermediates, and cleaning agents may benefit from an ADE. Problems in setting ADEs for these additional substances typically relate to toxicological data limitations precluding the ability to establish a formal ADE. Established methodologies such as occupational exposure limits or bands (OELs or OEBs) and the threshold of toxicological concern (TTC) can be used or adjusted for use as interim ADEs when only limited data are available and until a more formal ADE can be established. Once formal ADEs are derived, it is important that the documents are routinely updated and that these updates are communicated to appropriate stakeholders. Another key operational consideration related to data-poor substances includes the use of maximum daily dose (MDD) in setting cross-contamination limits. The MDD is an important part of the maximum allowable/safe concentration (MAC/MSC) calculation and there are important considerations for its use and definition. Finally, other considerations discussed include operational aspects of setting ADEs for pediatrics, considerations for large molecules, and risk management in shared facilities.
Asunto(s)
Industria Farmacéutica , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Animales , Relación Dosis-Respuesta a Droga , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Guías como Asunto , Política de Salud , Humanos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Medición de Riesgo , Pruebas de ToxicidadRESUMEN
A literature review and analysis of inhalation bioavailability data for large therapeutic proteins was conducted in order to develop a practical estimate of the inhalation bioavailability of these drugs. This value is incorporated into equations used to derive occupational exposure limits(OELs) to protect biopharmaceutical manufacturing workers from systemic effects. Descriptive statistics implies that a value of 0.05, or 5% is an accurate estimate for large therapeutic proteins (molecular weight ≥ 40kDa). This estimate is confirmed by pharmacokinetic modeling of data from a human daily repeat-dose inhalation study of immunoglobulin G. In conclusion, we recommend using 5% bioavailability by inhalation when developing OELs for large therapeutic proteins.
Asunto(s)
Exposición por Inhalación , Pulmón/metabolismo , Exposición Profesional/normas , Proteínas/farmacocinética , Seguridad , Disponibilidad Biológica , Humanos , Inmunoglobulina G/metabolismo , Concentración Máxima Admisible , Exposición Profesional/análisis , Preparaciones Farmacéuticas/análisis , Proteínas/uso terapéutico , Valores Limites del Umbral , Lugar de TrabajoRESUMEN
There is no nationally or internationally binding definition of the term "cytotoxic drug" although this term is used in a variety of regulations for pharmaceutical development and manufacturing of drugs as well as in regulations for protecting medical personnel from occupational exposure in pharmacy, hospital, and other healthcare settings. The term "cytotoxic drug" is frequently used as a synonym for any and all oncology or antineoplastic drugs. Pharmaceutical companies generate and receive requests for assessments of the potential hazards of drugs regularly - including cytotoxicity. This publication is intended to provide functional definitions that help to differentiate between generically-cytotoxic cancer drugs of significant risk to normal human tissues, and targeted cancer therapeutics that pose much lesser risks. Together with specific assessments, it provides comprehensible guidance on how to assess the relevant properties of cancer drugs, and how targeted therapeutics discriminate between cancer and normal cells. The position of several regulatory agencies in the long-term is clearly to regulate all drugs regardless of classification, according to scientific risk based data. Despite ongoing discussions on how to replace the term "cytotoxic drugs" in current regulations, it is expected that its use will continue for the near future.
Asunto(s)
Antineoplásicos/efectos adversos , Terapia Molecular Dirigida , Neoplasias/tratamiento farmacológico , Antineoplásicos/farmacología , Industria Farmacéutica , Humanos , Exposición Profesional/prevención & control , Preparaciones Farmacéuticas/clasificación , Terminología como AsuntoRESUMEN
During the chemical and pharmaceutical production of active pharmaceutical substances which are intended for immunosuppressive therapy, the employees may be exposed to these substances via inhalation. Immunosuppressants are linked to development of certain types of cancers e.g., lymphoma or skin cancer in transplant patients. The development of these cancers in patients is linked to the level of immunosuppression needed for transplantation in order to avoid organ rejection. Below these levels, with the immune system functioning uninhibited, cancer is unlikely to develop. An internal workshop was conducted to compare several pharmaceutical substances with the intrinsic property to cause immunosuppression, with the attempt to define the risk of healthy employees to develop cancer due to exposure to immunosuppressive substance at work and to determine the appropriate hazard classification for regulatory purposes. Data are discussed with emphasis on cyclosporine to reason the dose-response relationship and the safe level for occupational exposure. Our review indicates that if the exposure to cyclosporine at the workplace is below the threshold necessary to induce immunosuppression, the risk to develop cancer is negligible. Non-mutagenic immunosuppressants do not contribute to malignancies in occupational setting if their air concentrations do not exceed the immunosuppressive threshold limited with occupational exposure limits (OELs), which is for cyclosporine 17.5µg/m(3).
Asunto(s)
Ciclosporina/toxicidad , Inmunosupresores/toxicidad , Neoplasias/inducido químicamente , Exposición Profesional/efectos adversos , Animales , Ciclosporina/administración & dosificación , Relación Dosis-Respuesta a Droga , Humanos , Inmunosupresores/administración & dosificación , Exposición por Inhalación/efectos adversos , Neoplasias/epidemiología , Neoplasias/patologíaRESUMEN
The toxicity of amiodarone Lek formulation (test formulation) was investigated after a single intravenous (i.v.) administration to mice and rats. When compared to the reference item, Cordarone (Cordarone(®); Wyeth Pharmaceuticals Inc., Collegeville, Pennsylvania, USA), median lethal dose (LD(50)) after i.v. administration in female mice was 294.0 mg/kg body weight (b.w.) for the test formulation and 227.5 mg/kg b.w. for Cordarone. In female rats after i.v. administration, the LD(50) value was 269.9 mg/kg b.w. for the test formulation and 192.4 mg/kg b.w. for Cordarone. By altering the particle size of amiodarone in the Lek formulation, we were able to improve the solubility of amiodarone, thereby decreasing the number and quantity of excipients needed for preparation of the i.v. formulation and, consequently, reduced the acute toxic effects observed in the present study.
Asunto(s)
Amiodarona/toxicidad , Antiarrítmicos/toxicidad , Nanopartículas/toxicidad , Animales , Relación Dosis-Respuesta a Droga , Excipientes/toxicidad , Femenino , Inyecciones Intravenosas , Dosificación Letal Mediana , Ratones , Ratones Endogámicos , Tamaño de la Partícula , Ratas , Ratas Wistar , Solubilidad , Suspensiones , Pruebas de ToxicidadRESUMEN
The determination of single high doses of active pharmaceutical ingredients (API) is used mostly to fulfill regulatory demands. Oral LD(50) values in animals for over 300 API were compared to the minimal effective therapeutic doses (METD) in humans in order to find a correlation between animal and human data. The highest correlation between human METD and animal LD(50) was found for the dog (R=0.323), the lowest for the rat (0.287). It was determined that acute oral LD(50) of rats have poor correlation with the METD, and cannot be used as a classification criteria into official acute toxic categories. Only 13% of API has been classified as fatal if swallowed according to the EU CLP regulation, none of the substances with very low therapeutic dose have been identified as EU CLP acute toxicity category 1. Substances with very low therapeutic doses, which could potentially have toxic effects in humans, are not identified with the use of oral LD(50) and current classification system. We propose that the acute toxicity based on rat LD(50) dose is not used as a basis for classification of pharmaceuticals, and that the METD is applied as basis for classification.